-+ 0.00%
-+ 0.00%
-+ 0.00%

Moleculin Biotech risks Nasdaq delisting after shares stay below $1 bid threshold

PUBT·09/18/2026 21:01:27
Listen to the news
Moleculin Biotech risks Nasdaq delisting after shares stay below $1 bid threshold
  • Moleculin Biotech received a Nasdaq staff determination letter on Sept. 15, 2026, flagging noncompliance with the $1 minimum bid rule.
  • Shares closed below $1 for 30 straight business days from July 31, 2026 through Sept. 11, 2026.
  • Nasdaq denied the standard 180-day cure period due to a 1-for-25 reverse split on Dec. 1, 2025.
  • A timely hearing request will stay any suspension or delisting while the Nasdaq panel reviews the case.
  • Continued listing remains uncertain if the stock fails to regain and hold the $1 bid threshold.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moleculin Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-030757), on September 18, 2026, and is solely responsible for the information contained therein.